title: Effect of the preventive-therapeutic administration of melatonin on mammary tumour-bearing animals.
abstract: Melatonin has been reported to be involved in the feedback between neuroendocrine and immune functions and to exert oncostatic actions. Likewise, this hormone seems to lengthen life span in healthy animals. As of present, most studies have analysed the therapeutic effect of melatonin on cancer growth, but few have tested the preventive effect of melatonin in reducing the risk of cancer. Thus, the aim of this study was to evaluate the preventive-therapeutic effects of melatonin on rats with DMBA-induced mammary tumours, and to examine the effect of melatonin on the first line of cell defence against cancer (macrophages and NK cells) and on some of the neuroendocrine factors that are involved in the development of tumours (prolactin and catecholamines). Melatonin treatment (5 mg/day/animal) began one month prior to DMBA (9,10-dimethyl-1,2-benzanthracene) administration to females Sprague Dawley rats. It was found that the treatment led to an increase in survival and in latency time in the tumour-bearing rats. Although the melatonin treatment did not influence either the phagocytic capacity of macrophages or the number of peripheral blood NK cells, it did stabilise the levels of prolactin by returning the concentrations of this hormone to those of the healthy animals. We conclude that melatonin can exert an oncostatic action, lengthening the survival time of mammary tumour-bearing animals, and suggest that this effect is due, at least in part, to regulating the neuroendocrine parameters of tumour-bearing animals, bringing them closer to their optimal physiological status.
authors.affiliation: Department of Physiology, Faculty of Science, University of Extremadura, 06071 Badajoz, Spain.
authors.forename: M C
authors.initials: MC
authors.lastname: Saez
authors.forename: C
authors.initials: C
authors.lastname: Barriga
authors.forename: J J
authors.initials: JJ
authors.lastname: Garcia
authors.forename: A B
authors.initials: AB
authors.lastname: Rodríguez
authors.forename: E
authors.initials: E
authors.lastname: Ortega
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D005260:Female; D007274:Injections, Intraperitoneal; D007694:Killer Cells, Natural / Q000276:immunology; D008264:Macrophages / Q000276:immunology; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000276:immunology / Q000517:prevention & control*; D008550:Melatonin / Q000008:administration & dosage*; D051381:Rats; D017207:Rats, Sprague-Dawley; D015996:Survival Rate
chemical_list: D000276:Adjuvants, Immunologic; D008550:Melatonin
references.citation: Nat Immun. 1996-1997;15(2-3):78-86
references.pmid: 9162266
references.citation: Cancer Res. 1988 Nov 15;48(22):6434-7
references.pmid: 3141044
references.citation: Cancer Res. 1976 Jan;36(1):18-22
references.pmid: 1247997
references.citation: J Pineal Res. 1990;8(3):269-76
references.pmid: 2380908
references.citation: J Pharm Pharmacol. 2002 Oct;54(10):1299-321
references.pmid: 12396291
references.citation: Neoplasma. 2000;47(4):227-9
references.pmid: 11043826
references.citation: Acta Pathol Jpn. 1987 Jul;37(7):1143-8
references.pmid: 3661196
references.citation: Crit Rev Oncol Hematol. 2003 Jun;46(3):221-34
references.pmid: 12791421
references.citation: J Cancer Res Clin Oncol. 1991;117(6):526-32
references.pmid: 1744157
references.citation: Cancer Res. 1994 May 1;54(9):2429-32
references.pmid: 8162592
references.citation: J Physiol Biochem. 2001 Sep;57(3):237-44
references.pmid: 11800286
references.citation: J Neuroimmunol. 2000 May 1;104(2):101-8
references.pmid: 10713348
references.citation: J Natl Cancer Inst. 1984 Jun;72(6):1411-6
references.pmid: 6427503
references.citation: Int J Immunopharmacol. 1993 May;15(4):463-8
references.pmid: 8365822
references.citation: Pharmacol Toxicol. 1997 Dec;81(6):265-70
references.pmid: 9444667
references.citation: J Pineal Res. 1989;6(3):221-31
references.pmid: 2496220
references.citation: Immunology. 1997 Aug;91(4):635-42
references.pmid: 9378506
references.citation: J Steroid Biochem. 1990 Aug 14;36(5):485-91
references.pmid: 2145477
references.citation: J Neuroimmunol. 2000 Sep 22;109(2):95-104
references.pmid: 10996211
references.citation: Curr Top Med Chem. 2002 Feb;2(2):113-32
references.pmid: 11899096
references.citation: J Immunol. 1994 Sep 15;153(6):2671-80
references.pmid: 8077674
references.citation: J Neuroimmunol. 1999 Mar 1;95(1-2):85-94
references.pmid: 10229118
references.citation: J Neural Transm. 1980;48(1):25-42
references.pmid: 6106045
references.citation: Cancer Res. 1985 Aug;45(8):3415-43
references.pmid: 3926298
references.citation: Proc Soc Exp Biol Med. 1990 Jun;194(2):103-7
references.pmid: 2349246
references.citation: Mech Ageing Dev. 2000 Sep 29;118(3):103-14
references.pmid: 11006444
references.citation: Folia Biol (Praha). 2001;47(1):5-10
references.pmid: 11232869
references.citation: Pathology. 1997 Aug;29(3):320-3
references.pmid: 9271027
references.citation: Adv Exp Med Biol. 1999;467:247-64
references.pmid: 10721063
references.citation: N Engl J Med. 1997 Jan 16;336(3):186-95
references.pmid: 8988899
references.citation: Cancer Immunol Immunother. 2002 Jan;50(11):604-14
references.pmid: 11807624
references.citation: Biol Signals. 1994 Mar-Apr;3(2):107-17
references.pmid: 7951648
references.citation: Neuro Endocrinol Lett. 2002 Aug;23(4):341-4
references.pmid: 12195238
references.citation: J Pineal Res. 2001 Jan;30(1):34-42
references.pmid: 11168905
references.citation: Cancer Lett. 2000 Aug 11;156(2):177-84
references.pmid: 10880767
references.citation: J Pineal Res. 1991 Apr;10(3):136-40
references.pmid: 1880709
references.citation: Environ Health Perspect. 1996 Sep;104(9):938-67
references.pmid: 8899375
references.citation: J Surg Oncol. 1996 Jun;62(2):86-92
references.pmid: 8649046
references.citation: J Pineal Res. 1992 Aug;13(1):13-9
references.pmid: 1432572